[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.82.105. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 746
Citations 0
Editorial
June 2015

A Reassuring Rejoinder Against Malignant Influences of Topical Calcineurin Use in Children

Author Affiliations
  • 1Department of Dermatology, Oregon Health and Science University, Portland
JAMA Dermatol. 2015;151(6):587-588. doi:10.1001/jamadermatol.2014.4306

The topical calcineurin inhibitors tacrolimus and pimecrolimus are useful and effective anti-inflammatory immunomodulator adjuncts in managing atopic dermatitis (AD). Unfortunately, because of the increased risk of lymphoma in transplant recipients receiving systemic tacrolimus and because of malignant neoplasms in animal studies with pimecrolimus, their use as topical agents has raised concerns.1 Yet the topical use of these drugs in humans since the mid-1990s has not appeared to cause any clear immunosuppressive propensity toward malignancy.

First Page Preview View Large
First page PDF preview
First page PDF preview
×